RE: Trading12 May 2023 16:50
I think there's nothing more to discuss really until we get to phase 1b and start to get dox comparisons.
The pre|CISION platform clearly works in the lead asset with therapeutic dox found in all tumour biopsies. It would be a bit of a waste of time too searching for a maximum tolerated dose of a drug that doesn't work.
Clearly there is a massive disconnect in the share price and the value of what avacta has. It's a platform that delivers drugs (any drugs) to the exact location that they are required.
With ava6000 that means eliminating or drastically reducing side effects, with one of the major ones being cardiotoxicity.
So yes I am convinced we are sitting on a unicorn and at some point, probably when tap announces that the standard of care for STS is now ava6000, it will explode in value.
Or one of the big pharmas will have already offered billions.
I also think all your posts entitled "trading" are garbage.
Thanks